Salk Institute Board of Trustees elects two visionary business leaders

December 9, 2013

Salk Institute Board of Trustees elects two visionary business leaders

December 9, 2013

LA JOLLA, CA—The Salk Institute is pleased to announce that Alan D. Gold and David F. Hale have been elected to its Board of Trustees.

“Alan and David each bring outstanding records of entrepreneurial success and business expertise to Salk,” said Irwin M. Jacobs, Chairman of the Salk Institute Board of Trustees. “We are greatly pleased to have them join our Board of Trustees.”

Alan D. Gold is chairman and chief executive officer of Biomed Realty, a publicly traded REIT specializing in acquiring and managing laboratory properties for lease to the life science industry. Mr. Gold also served as president of BioMed’s privately held predecessor, Bernardo Property Advisors, Inc. He was a co-founder and served as president and as a director of Alexandria Real Estate Equities, Inc. He was managing partner of GoldStone Real Estate Finance and Investments, a partnership engaged in the real estate and mortgage business. He also served as assistant vice president of Commercial Real Estate for Northland Financial Company, a full service commercial property mortgage banker, and as Real Estate Investment Officer – Commercial Real Estate for John Burnham Company, a regional full service real estate company. He currently serves on the Campanile Foundation Board supporting San Diego State University.

David F. Hale is chairman and chief executive officer of Hale BioPharma Ventures, LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic, and medical device companies. He also serves as executive chairman of Biocept, Inc., a cancer diagnostic company working on the detection and analysis of circulating tumor cells. Previously, he was president and chief executive officer of CancerVax Corporation from October 2000 through its merger in May 2006 with Micromet, Inc. where he served as chairman until its acquisition by Amgen Inc. in 2012. Additionally, Mr. Hale is chairman of Santarus, Inc., and a founding director and chairman of Conatus Pharmaceuticals, Inc. He is a co-founder and chairman of numerous other companies. Mr. Hale currently serves on the board of directors of BIOCOM, which he co- founded, and the San Diego Economic Development Corporation. He is a former member of the board of the Biotechnology Industry Organization (BIO) and the Biotechnology Institute. He is a co-founder and a director of CONNECT, acts as chairman of the board of trustees of Rady Children’s Hospital, and is a member of Rady School of Management Dean’s Advisory Council.

Über das Salk Institute for Biological Studies:
Das Salk Institute for Biological Studies ist eine der weltweit führenden Institutionen für Grundlagenforschung, an der international renommierte Fakultätsmitglieder grundlegende Fragen der Biowissenschaften in einem einzigartigen, kollaborativen und kreativen Umfeld untersuchen. Mit dem Fokus auf Entdeckungen und die Ausbildung zukünftiger Forschergenerationen leisten Salk-Wissenschaftler bahnbrechende Beiträge zu unserem Verständnis von Krebs, Alterung, Alzheimer, Diabetes und Infektionskrankheiten durch die Untersuchung von Neurowissenschaften, Genetik, Zell- und Pflanzenbiologie sowie verwandten Disziplinen.

Die Leistungen der Fakultät wurden mit zahlreichen Auszeichnungen gewürdigt, darunter Nobelpreise und Mitgliedschaften in der National Academy of Sciences. Das 1960 vom Polio-Impfstoff-Pionier Dr. Jonas Salk gegründete Institut ist eine unabhängige gemeinnützige Organisation und ein architektonisches Wahrzeichen.